Heron Therapeutics Inc  

(Public, NASDAQ:HRTX)   Watch this stock  
Find more results for NASDAQ:APPA
16.52
-0.13 (-0.78%)
After Hours: 16.52 0.00 (0.00%)
Jul 25, 4:41PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 16.20 - 16.94
52 week 15.22 - 42.25
Open 16.65
Vol / Avg. 264,681.00/462,369.00
Mkt cap 622.80M
P/E     -
Div/yield     -
EPS -3.17
Shares 36.66M
Beta 1.30
Inst. own 128%
Aug 5, 2016
Q2 2016 Heron Therapeutics Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
Jul 12, 2016
Heron Therapeutics Inc at Cantor Fitzgerald Healthcare Conference
Jun 22, 2016
Heron Therapeutics Inc at JMP Securities Life Sciences Conference
Jun 7, 2016
Heron Therapeutics Inc at Jefferies Healthcare Conference
May 10, 2016
Heron Therapeutics Inc at Bank of America Merrill Lynch Health Care Conference - Webcast
May 5, 2016
Q1 2016 Heron Therapeutics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -107.45% -90.98%
Return on average equity -127.28% -107.73%
Employees 148 -
CDP Score - -

Address

123 Saginaw Dr
REDWOOD CITY, CA 94063-4717
United States - Map
+1-650-3662626 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Heron Therapeutics, Inc. is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company's product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology. The Company's SUSTOL (granisetron) injection, extended release is being developed for the prevention of both acute and delayed chemotherapy-induced nausea and vomiting (CINV) associated with moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC). HTX-019, which is an intravenous formulation of aprepitant, a neurokinin-1 (NK1) receptor antagonist, is being developed for the prevention of CINV. HTX-011, a long-acting formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam, is being developed for the prevention of post-operative pain. HTX-011 is in Phase II clinical trials.

Officers and directors

Kevin C. Tang Independent Chairman of the Board
Age: 48
Bio & Compensation  - Reuters
Robert Harvey Rosen President, Director
Age: 60
Bio & Compensation  - Reuters
Barry D. Quart Pharm.D. Chief Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Brian G Drazba Chief Financial Officer, Vice President - Finance
Age: 53
Bio & Compensation  - Reuters
Neil James Clendeninn M.D. Ph.D. Senior Vice President and Chief Medical Officer
Age: 66
Bio & Compensation  - Reuters
Paul G. Marshall Senior Vice President - Technical Operations
Age: 55
Bio & Compensation  - Reuters
Esme C. Smith Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Stephen R. Davis Director
Age: 54
Bio & Compensation  - Reuters
Christian Waage Director
Age: 49
Bio & Compensation  - Reuters
Craig A Johnson Independent Director
Age: 54
Bio & Compensation  - Reuters